Protease-activated nanoshell therapy by Morton, Jennifer Garner
RICE UNIVERSITY 
Protease-Activated Nanoshell Therapy 
by 
Jennifer Garner Morton 
A THESIS SUBMITTED 
IN PARTIAL FULFILLMENT OF THE 
REQUIREMENTS FOR THE DEGREE 
Master of Science 
APPROVED, THESIS COMMITTEE: 
Jennifer West 
Bioengineering 
Xj-, ^ - - i ^ M 
, Professor, Chair 
skah Drezek, Associate I Rebe Professor 
Bioengineering 
JasoifHafner, Associate Professor 
Physics and Astronomy 
HOUSTON, TEXAS 
APRIL, 2009 
UMI Number: 1466808 
INFORMATION TO USERS 
The quality of this reproduction is dependent upon the quality of the copy 
submitted. Broken or indistinct print, colored or poor quality illustrations 
and photographs, print bleed-through, substandard margins, and improper 
alignment can adversely affect reproduction. 
In the unlikely event that the author did not send a complete manuscript 
and there are missing pages, these will be noted. Also, if unauthorized 
copyright material had to be removed, a note will indicate the deletion. 
® UMI 
UMI Microform 1466808 
Copyright 2009 by ProQuest LLC 
All rights reserved. This microform edition is protected against 
unauthorized copying under Title 17, United States Code. 
ProQuest LLC 
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106-1346 
ABSTRACT 
Protease-Activated Nanoshell Therapy 
by 
Jennifer Morton 
This thesis describes the development of photothermal nanoshell therapy 
activated by proteases. Hirsch et al. previously showed that the optical spectrum of 
crosslinked nanoshells within the UV-visible range reveals a broader, red-shifted, and 
lower peak absorbance as compared to disperse nanoshells. As described in this thesis, 
studies showed this decrease in absorbance corresponds with a lower temperature change 
upon laser irradiation of the nanoshells. Near infrared (NIR)-absorbing silica-gold 
nanoshells were crosslinked with a proteolytically degradable linker, resulting in a 
broadening, red-shifting, and decrease of the peak absorbance. After collagenase was 
added to the crosslinked nanoshells, the peak absorbance increased, suggesting 
degradation of the linker and subsequent dispersion of the nanoshells. The results 
described here suggest that this may be applied to protease-activation in vivo within the 
tumor in an effort to increase tumor specificity and to protect surrounding normal tissue. 
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Chapter 1: Introduction 
1.1 Introduction 
Cancer is responsible for one out of every four deaths in the United States. For 
2007, the American Cancer Society (ACS) estimates $206.3 billion in total cancer-related 
costs and 1,444,920 new cases[l]. In 2006, the U.S. Center for Disease Control (CDC) 
released a report of cancer incidence and mortality in 2003. This publication reports 
prostate cancer as being the leading cancer type among men and lung cancer being the 
leading cause of cancer death. Breast cancer is reported as being the leading cancer type 
among women and the second leading cause of cancer death behind lung cancer[2]. 
1.2 Cancer Biology 
The term "cancer" refers to a disease of unchecked cell proliferation resulting in 
the formation of a tumor mass [3]. Defects in the cell division regulatory systems are 
caused by mutations in cellular DNA, specifically up-regulation of proto-oncogenes and 
loss of function of tumor suppressor genes. In normal cells, proto-oncogenes encode 
proteins involved in the growth and differentiation of cells. Mutation results in 
transformation into oncogenes, which allow for uncontrolled proliferation and lack of or 
incorrect differentiation. Tumor suppressor genes exist to inhibit cell proliferation when 
necessary and the loss of function likewise results in unchecked cell proliferation[3]. The 
physiology of the cancer cell acquires several characteristics that ultimately lead to 
malignant growth. These include production of their own growth signals and signal 
receptors, insensitivity to anti-growth signals from surrounding cells, apoptosis evasion, 
limitless replicative potential, sustained angiogenesis, and tissue invasion and metastasis, 
which is the major cause of cancer-related death[4]. 
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Figure 1 The hallmarks of cancer include self-sufficiency in growth signals, insensitivity to anti-growth 
signals, tissue invasion and metastasis, limitless replicative potential, sustained angiogenesis, and evading 
apoptosis. Adapted from Hanahan, 2000[4], 
Due to the highly active angiogenesis and vascular remodeling, tumor vasculature 
is characteristically irregular (Figure 2). The vessels are disorganized, dilated, and of 
uneven diameter and excessive 
branching[5, 6], resulting in chaotic 
blood flow subsequently leading to 
hypoxic and acidic regions in the 
tumor[7]. 
The basement membrane is discontinuous 
or absent and the pericytes and 
endothelial cells are irregularly shaped. 
The endothelial cells do not form a 
Normal 
Figure 2 Tumor vasculature is irregular 
compared to normal tissue. The vessels of 
tumors are dilated, disorganized, and of 
uneven diameter and excessive branching. 
From Jain, 2005. 
3 
continuous monolayer[8, 9] due to their loose interconnections and focal intercellular 
openings. These openings have been shown to be up to 2 \im in diameter[10]. These 
characteristics lead to tumor vessels being dramatically more leaky than normal 
vessels[10]. By delivering nanospheres of various sizes to the tumor, Hobbs et al. 
demonstrated that particles from up to 780 nm in size could be delivered preferentially to 
subcutaneous tumors through the leaky vasculature[l 1]. 
Along with a dysfunctional vasculature, the solid tumor is also absent of 
functional lymphatics[12]. The lack of lymphatic clearance from the tumor interstitial 
space combined with the enhanced leakiness of the tumor vasculature has been 
characterized as the tumor-selective enhanced permeability and retention (EPR) 
effect[13]. This characteristic of tumors is taken advantage of in multiple tumor 
treatment methods. 
1.3 MMPs in Tumor Metastasis 
Tumor invasion and metastasis is a multi-step process in which the cancer cells 
detach from the tumor mass, intravasate into the blood circulation, extravasate from the 
circulation at a distant site, and form a secondary tumor in a new organ environment^]. 
During this process, the extracellular matrix and basement membrane are digested by a 
family of secreted or transmembrane enzymes known as matrix metalloproteases 
(MMPs)[14]. 
Metalloproteases are a class of hydrolytic enzymes that rely on zinc for catalytic 
activation. The matrixin subfamily (MMPs) consists of metalloproteases that display 
proteolytic activity outside the cell, a conserved sequence around the cysteine residue in 
the propeptide, and a zinc-binding sequence, and are inhibited by tissue inhibitor of 
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metalloproteinase-1 (TIMP-1)[15]. The structure of MMPs, shown in Figure 3, consists 
of a signal sequence, followed by a propeptide domain, a catalytic domain, a hinge 
region, and a hemopexin domain[16]. The inactive state (proMMP) is retained by an 
interaction between a cysteine residue in the propeptide domain and a Zn+ in the catalytic 
domain. Dissociation of this reaction results in activation of the enzyme[15]. 
Sigfial/Prodomain Catalytic Domain Hinge Hemopexin 
PRCGVPD h e 9 i % 
'"IT" 
i t 
Figure 3 The structure of matrix metalloproteases (MMPs) consist of a signal sequence, propeptide 
domain, catalytic domain, a hinge region, and a hemopexin. From www.emdbiosciences.com[17]. 
MMPs can be both secreted as soluble enzymes or membrane-bound and are 
divided into subgroups based on substrate specificity[15]. These categories include 
collagenases (MMP-1, MMP-8, and MMP-13), gelatinase A (MMP-2) and gelatinase B 
(MMP-9), stromelysins (MMP-3, MMP-10, and MMP-11), and a metalloelastase (MMP-
12), the majority of which are secreted, and membrane-type MMPs (MT-MMPs) which 
are membrane-bound[14]. MMPs are used to degrade the ECM in normal physiological 
functions including embryonic development, wound healing, and angiogenesis[15]. 
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Figure 4 Roles of MMPs in tumor progression and angiogenesis[18]. 
Gelatinase A (MMP-2) degrades the basement membrane components type IV 
collagen and laminin[19] and has been identified in metastatic tumors[20, 21]. MT1-
MMP, which degrades type I and II collagens, fibronectin, vitronectin, laminin, fibrin, 
and proteoglycan, activates proMMP-2, the inactive form of MMP-2[22]. MT1 -MMP 
has been shown to be present in high levels in many malignant tumor tissues[23]. As a 
result, high levels of activated MMP-2 has been shown in many types of human cancers, 
including oral[24], gastric[25], lung[26], prostate[27], ovarian[28, 29], bladder[30], and 
breast[31]. MMP-9, also known as gelatinase B, also plays an important role in tumor 
initiation, growth, and metastasis[14]. Its expression has been shown to correlate with 
metastatic potential[32]. 
Unlike the majority of MMPs that are secreted predominantly by stromal cells of 
the tumor, matrilysin (MMP-7) is produced by the tumor cells[33]. This protease is 
overexpressed in cancers of the digestive system as well as that of the lung, skin, prostate, 
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breast, and head and neck[33]. Matrilysin degrades ECM substrates such as elastin, type 
IV collagen, fibronectin, and laminin[34] and activates proMMP-2 and proMMP-9[35]. 
1.4 Cancer Therapy 
Easily accessible benign tumor masses can be removed through surgery. For 
malignant tumors or those that cannot be safely surgically removed, additional methods 
of treatment are required. Radiation therapy seeks to damage the DNA of rapidly 
dividing cells in order to disrupt the cell cycle and subsequently halt cell growth. The 
ionizing radiation can be administered from either an external or internal source[36]. 
External beam radiation therapy (EBRT) delivers high doses of X-rays to the tumor area, 
located by computed tomography (CT) scan. Three-dimensional conformal radiotherapy 
(3D-CRT) shapes the beams to the shape of the tumor, thereby reducing the amount of 
normal tissues exposed to the radiation[37]. Intraoperative radiation therapy (IORT) 
applies radiation during surgery in order to treat localized tumors that cannot be 
completely removed surgically[3 6, 38]. Internal radiation (brachytherapy) involves 
applying radiation in very close proximity to the tumor area through an implant including 
balloons[39], catheters, hollow needles[40], among others. 
The goal of chemotherapy drugs is to damage the DNA in rapidly dividing cells in 
order to slow or completely halt the cell cycle. Specific chemotherapeutic drugs and their 
mechanism of action are summarized in Table 1. 
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Table 1 Commonly used chemotherapy drugs and their mechanisms of action 
Drug Type 
Alkylating Agents 
Anti-metabolites 
Nitrosoureas 
Plant Alkaloids 
Topoisomerase 
Inhibitors 
Antitumor 
Antibiotics 
Corticosteroid 
Hormones 
Mechanism of 
Action 
Alkylates oxygen 
and nitrogen atoms 
innucleotides[41] 
Incorporates into 
DNA - recognized 
by mismatch repair 
system - cell cycle 
arrest[421 
Crosslinks guanine 
and cytosine on 
opposite DNA 
strands[41] 
Inhibit mitosis 
Inhibit enzymes that 
catalyze relaxation 
of supercoiled 
DNAK21 
Inhibits 
topoisomerase II; 
generates free 
radicals 
Prevent 
phospholipids 
release, decrease 
eosinophil action; 
promote Na+ 
retention in kidney 
Cancer Types 
Leukemia, Hodgkin 
disease, multiple 
myeloma, lung, 
breast, ovarian 
Leukemia, breast, 
ovary, GI tract, 
colon 
Brain, lymphoma, 
multiple myeloma, 
malignant myeloma 
Breast, lung, 
myeloma, 
lymphoma, 
leukemia 
Leukemia, lung, 
ovarian, GI tract 
Leukemia, breast, 
bladder, lung, 
ovaries 
Lymphoma, 
leukemia, multiple 
myeloma 
Examples 
Busulfan, cisplatin, 
carboplatin, 
chlorambucil, 
ifosfamide 
5-fluorouracil, 6-
mercaptopurine, 
methotrexate 
Streptozocin, 
carmustine, 
lomustine 
Taxanes (paclitaxel, 
docetaxel) and vinca 
alkaloids 
(vinblastine, 
vincristine) 
Topotecan, 
etoposide 
Daunorubicin, 
doxorubicin, 
mitoxantrone 
Prednisone, 
solumedrol, 
dexamethasone 
Because chemotherapy is normally administered systematically, normal healthy cells are 
often damaged along with the cancer cells, resulting in many unwanted side effects such 
as nausea and hair loss. In order to lessen the side effects that result from systemically 
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administering DNA-damaging drugs, other strategies have been developed including the 
use of angiogenesis inhibitors[43] and photodynamic therapy[44]. 
1.5 Nanoparticles in Cancer Therapy and Diagnostics 
The use of nanoparticles in the tumor-selective delivery of anticancer agents and 
as contrast agents for in vivo tumor imaging has been explored. Nanoparticles potentially 
provide the ability to shield healthy tissue from the exposure to cytotoxic anticancer 
drugs while en route to the tumor. Anthracycline agents, such as doxorubicin have been 
encapsulated in liposomes (100 nm diameter) in an effort to reduce its cytotoxic 
effects [45, 46]. Due to their hydrophobicity, taxanes such as paclitaxel and docetaxel 
must be transported to the tumor site in synthetic vesicles. These synthetic materials 
often exert cytotoxic effects. Cremophor EL (CrEL), the surfactant utilized in the 
solubilization of paclitaxel, induces acute hypersensitivity and neurotoxic effects[47]. 
The use of non-synthetic materials as a delivery vehicle is being explored. Albumin-
encapsulated taxanes have shown both effectiveness in tumor penetration and low 
toxicity[48]. Dendrimers and carbon nanotubes are also currently being explored in 
potential drug delivery methods[49, 50]. 
Nanoparticles are gaining attention as potential contrast agents in various imaging 
methods because of the ability to functionalize the nanoparticle surface with targeting 
moieties. Magnetic nanoparticles encapsulated by a gold shell are being explored 
potential contrast agents for MRI[45, 51]. Polymer-encapsulation is an effective means 
of delivering contrast agents that are not effective when uncoated. Bismuth is stable at 
high concentrations, has an X-ray absorption five times higher than iodine, demonstrates 
long in vivo circulation times, and expresses an efficacy/safety profile comparable to that 
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of iodine[52]. Bismuth, however, is not effective when uncoated because of nanocrystal 
aggregation at physiologic pH and potential plasma protein adsorption on the surface[52]. 
Rabin et al. coated bismuth nanoparticles in polyvinylpyrrolidone (PVP) and 
demonstrated its efficacy as a contrast agent in CT imaging[52]. 
Quantum dots are a potential alternative to in vivo organic immunofluorescence. 
Quantum dots are semiconductor nanoparticles that are detectable in vivo under NIR light 
when made to emit in the near-infrared spectrum[45]. These quantum dots can therefore 
be surface-functionalized with tumor-targeting agents and utilized for in vivo tumor 
localization. 
1.6 Nanoshell Therapy and Imaging 
Nanoshells are optically tunable nanoparticles consisting of a dielectric core and a 
thin metal shell. These particles can be designed to primarily scatter or absorb light 
based on the core and shell dimensions. A larger core results in greater scattering 
contribution to the total extinction while a smaller core typically induces primarily 
absorbing properties. The location of the peak extinction within the spectrum is 
dependent upon the ratio of the core radius to shell thickness, as demonstrated in Figure 
5. A thinner shell induces a shift of peak extinction to the longer wavelengths, while a 
thicker shell produces a peak blueshift[53]. 
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Figure 5 The optical properties of nanoshells are dependent on the core size/shell thickness ratio. With a 
dielectric core of the same size, a thinner gold shell results in a redshifted peak while a thicker shell pushes 
the peak to shorter wavelengths[53]. 
Due to their ability to either scatter or absorb light, nanoshells possess great 
potential in both imaging and therapeutic applications, specifically optical imaging and 
photothermal ablation of tumors. Other applications include tissue welding[54] and 
probes for antigen detection in whole blood[55]. This section describes in detail the 
development of nanoshells, their physical optical properties, and their use in tumor 
therapeutic and imaging applications. 
1.6.1 Optical Properties of Nanoshells 
Nanoparticles with a dielectric core of Au2S and a gold shell were the first 
core/shell nanoparticle to be described experimentally[46, 56, 57]. These nanoparticles 
are formed by mixing aqueous solutions of Na2S and HAuCl4. The proposed reaction of 
the reduction process is 
2AuCl4" + 3HS- «* 2Au + 3S + 3H+ + 8C1\ 
after which Au and S are available for nucleation and growth. Under these reaction 
conditions, both Au particles and Au-coated Au2S particles are grown simultaneously. A 
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two-stage growth model of the Au2S particles is proposed in which a linear increase in Au 
shell thickness follows linear growth of the core radius. The growth of the core radius 
contributes to the redshift of the near infrared peak and upon reaching a constant size, the 
peak takes a turn towards smaller wavelengths as the shell thickness increases[46]. 
Figure 6 shows spectra are taken at various time points during particle growth where the 
presence of two peaks is observed. The largest peak, located at 530nm, is attributed to 
the pure gold particles present in the solution. The second peak, in the near infrared 
region, starts out almost non-existent then grows larger as the reaction proceeds, initially 
shifting toward longer wavelengths and then taking a sudden blueshift turn. 
Figure 6 UV-visible spectra of gold-gold sulfide nanoshells taken at various time points during particle 
growth show the plasmon resonance shifts initially toward longer wavelengths and then blueshifts[46]. 
Nanoshells are unique nanoparticles in that their optical properties are dependent 
on the core diameter to shell thickness ratio. This property is described by the Mie 
theory, the solution for the Maxwell equations for a dilute colloidal system. Extending 
the Mie theory to nanoparticles with a metal shell involves specifying the boundary 
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conditions at one additional interface, that of the core and shell. Because r « X for these 
nanoparticles, where r is the particle radius and X is the wavelength of the incident 
electromagnetic field, the quasi-static approach can be used in order to simplify Mie 
theory calculations. In this model, the electromagnetic incident field does not vary 
spatially over the diameter of the diameter of the metal shell and therefore the spatial 
variance is neglected in the calculations. The time-dependence of the incident wave, 
however, is preserved. For further simplification, the nanoshells are assumed to be 
perfectly spherical and interactions between nanoparticles are neglected due to the low 
nanoshell concentration[56]. 
Averitt et al. derived and described this quasi-static theory of nanoshells[56]. The 
geometry of the nanoshell is shown in Figure 7 where ri is the core radius, r2 is the total 
particle radius, and £1, e2, and e3 are the dielectric constants of the core, shell, and medium, 
respectively. 
Figure 7 The geometry of a nanoshell. n is the core radius while r2 is the total particle radius. Ei, e2, and e3 
are the dielectric constants of the core, shell, and medium, respectively[56]. 
Applying the Mie scattering theory, the absorption cross section of the nanoshells 
obtained is described by Equation 2 
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is 
Oabs = —Ma)> Equation 2 
where the polarizability (a), the tendency of charge distribution to be distorted by an 
external electric field, is described by Equation 3 
or = 4jt£gr2~ hh-Mb 
£2ea+2e3e„ 
Equation 3 
Combining Equations 2 and 3, the absorption cross section is given as 
$JI2Je*
 3 T [ £ , , £ - £ , £ . 
\£2£a +2£3f6 / 
where 
Equation 4 
ea=el(3-2P) + 2e2P, Equation 5 
eb=£lP + e2(3-P), 
and P, the shell volume to total particle volume ratio, is described by 
Equation 6 
P-i-W Equation 7 
Similarly, the scattering cross section is described as 
°sca = 
128JT 2 6 
3A4 3 2 
£2£a £3£b 
e2sa + 2e3£6 
Equation 8 
Figure 8 shows the nanoshell extinction cross sections using Equations 3 and 7 where 
r 2=4. 10, 17. 
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Wavetenfth (nm) 
Figure 8 Calculations of the nanoshell absorption and scattering cross sections with a shell thickness of 2 
and r2 = 4,10,17 indicates that, for a given shell thickness, a larger core diameter yields a plasmon 
resonance shifted to longer wavelengths[56]. 
This demonstrates the dependency of the resonance wavelength on the ratio of core 
radius to total particle radius. For a given shell thickness, a larger particle diameter 
yields a peak plasmon resonance in the longer wavelengths[56]. 
The plasmon resonance of the electrons in the metal shell occurs at the point of 
maximum polarizability. From Equation, it can be seen that this is when the denominator 
approaches zero (E2Ea+ 2838b -» 0). From Equation and the previous definitions, Averitt 
et al developed the following expression describing the plasmon resonance as a function 
of wavelength if both the core and embedding medium are dielectrics: 
am 
h 
when t2 « X, shell thickness (r2 - ri) is greater than a few atomic layers. This expression 
demonstrates the fact that the wavelength of plasmon resonance is dependent on the 
core/shell geometry of the particle [5 6]. 
1 + £
'(A)(£l+2g3) 
2[£;(A)]2-£;(A)(£l + £ 3)+{^3-[£ ; ' (A)]2} 
Equation 9 
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Due to the tunability of the optical properties, the ability to control the core and 
shell dimensions is desirable. Oldenburg et al. developed a nanoshell with a dielectric 
silica core and a gold shell[53]. The silica cores are made using the Stober method in 
which tetraethyl orthosilicate is reduced in ammonium hydroxide (NH4OH) in ethanol. 
The size of the silica particles is correlated with the amount of NH4OH added to the 
solution, therefore providing control over core size. The shell is formed by reducing gold 
colloid particles on the surface of the core. The size of the shell is dependent on the 
relative amount of gold to silica cores during the reduction process, thereby providing 
control over the shell thickness. 
1.6.2 Optical Properties of Crosslinked Nanoshells 
When nanoshells are cross-linked, the peak extinction red-shifts, broadens, and 
decreases (Figure 9). 
400 500 600 700 800 900 1000 
Wavelength (nm) 
Figure 9. Crosslinked nanoshells experience a red-shifting, broadening, and decrease in peak 
extinction[55]. 
This is due to the fact that nanoshells that are linked together in very close proximity are 
acted upon by the dipole fields of the other particles in the aggregate as well as the 
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incident field. The absorption cross-section of nanoparticle aggregates is described by 
the equation 
Cabs = r r i f 2{MP,- '(aJ-l)*V'}-h3Vj -P';}, Equation 10 
III- : 1 ^ 
I inc\ J=i 
which represents a summation of the rate of energy dissipation by each of the dipoles. 
The first term of the summation (P, • (a/')*P*) represents the energy of the incident 
electromagnetic field. The second term ((2/3)^3P/) represents the combined electric field 
experienced byy due to the other N-l dipoles, also known as the radiative reaction.[58, 
59]. 
1.6.3 Nanoshell-Assisted photothermal therapy 
The tunability of nanoshells enables potential use in biological applications in that 
they can be designed to strongly absorb light in the near infrared (NIR) region (650-900 
nm). In this range, the absorption coefficients of water and hemoglobin are at their 
lowest, and therefore light is able to penetrate deeply into tissues (Figure 10) [60]. 
400 590 690 780 809 990 1090 
Wavelength (nm) 
Figure 10 In the NIR window, the absorption coefficients of water and hemoglobin are at their lowest, 
enabling light of wavelengths within this range to deeply penetrate tissue[60] 
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When injected systemically, NIR-absorbing nanoshells have been shown to extravasate 
out of the leaky tumor vasculature where, when irradiated with a NIR laser, they generate 
heat, resulting in photothermal destruction of the tumor[61]. This section describes the 
development of this method known as nanoshell-assisted photothermal therapy (NAPT). 
The first use of nanoshells in photothermal ablation of tumors was shown by 
Hirsch et al. in 2003 [62]. SKBr3 human breast epithelial carcinoma cells were incubated 
in vitro with nanoshells and then irradiated with NIR light. Cells without nanoshells 
were irradiated with the laser as a control. Calcein AM staining (Figure 11) revealed a 
circle of cell death corresponding to the spot size of the laser in the nanoshell-treated 
shells and no death in the cells that were treated with the laser only. Fluorescein-dextran, 
a high molecular-weight dye impermeable to healthy cells, was shown to penetrate the 
membranes of the cells receiving the nanoshell/laser treatment. This implies that cell 
membrane destruction is a mechanism involved in cell death resulting from 
nanoshell/laser treatment. 
Lasaonly NaiidsheJls+Laser 
Figure 11 Calcein AM staining shows cell death in those cells receiving nanoshell treatment (a,b). High 
molecular weight dye indicates membrane destruction as the mechanism of cell death (c,d)[62]. 
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In addition to the previously mentioned study, nanoshell treatment of tumors in 
mice and the resultant heat profiles within the tumors were investigated[62]. Mice were 
inoculated with canine TVT cells on both hind legs. After the tumors reached a diameter 
of 1 cm, nanoshells were injected interstitially into the tumor. Prior to injection, the 
nanoshell surfaces were functionalized with poly(ethylene glycol) thiol (PEG-SH) to 
provide steric stabilization and to minimize aggregation due to protein adsorption in the 
physiological environment. Five to thirty minutes after injection, the tumor sites were 
exposed to the NIR laser. Magnetic resonance thermal imaging (MRTI) was used to 
monitor the temperature distribution within the tumor during treatment. Nanoshell-
treated tumors resulted in an average temperature increase of 37.4 ± 6.6°C, high enough 
to cause irreversible tissue damage, while nanoshell-free controls experienced an average 
temperature increase of only 9.1 ± 4.7°C. Gross pathology, silver staining, and histology 
of the tumors indicated edema, coagulation, cell shrinkage, and loss of nuclear staining in 
the same area as the localized nanoshells (Figure 12) [62]. 
1 1 1 1 1 1 
lcm 
Figure 12 Analysis of an excised tumor from a mouse receiving nanoshell-assisted photothermal therapy 
reveals that the area of tissue damage coincides with the area of localized nanoshells. (a) gross pathology 
reveals hemorrhaging, (b)silver staining reveals the area of localized nanoshells, (c) hematoxylin/eosin 
staining reveals the area of tissue damage, and (d) MRTI calculations reveal the area of irreversible 
thermal damage[62]. 
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O'Neal et al. investigated NAPT in mice with delivery to the tumor site through 
the vasculature[61]. Mice were inoculated subcutaneously with CT26 colon carcinoma 
tumor cells and when the tumor reached 3-5.5 mm diameter, PEGylated nanoshells were 
injected into the tail vein. To allow enough time for the nanoshells to accumulate in the 
tumor site, laser treatments were performed 6 hours after nanoshell injection. Within 10 
days of treatment, complete resorption of the tumors was observed in the nanoshell-
treatment group (Figure 13) and 90 days after treatment, all nanoshell-treated mice were 
healthy and tumor-free. Tumors in the control groups continued to grow rapidly and all 
mice were euthanized by day 19 due to excessive tumor growth. 
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Figure 13 Meant tumor size measured on treatment day (day 0) and 10 days post-treatment. All tumors 
receiving NAPT showed resorption after 10 days[61]. 
1.6.4 Immunotargeted Nanoshells 
In order to increase nanoshell specificity to the tumor site, targeting the 
nanoshells with antibodies against overexpressed cell-surface oncoproteins has been 
investigated[63]. In order to target human epidermal growth factor receptor 2 (HER2), 
which is over-expressed on human breast cancer cells, nanoshells were targeted using the 
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anti-HER2 antibody. HER2+ SKBr3 cells were incubated with antibody-functionalized 
nanoshells and then irradiated with a NIR laser. Nanoshells conjugated to anti-IgG, a 
nonspecific control antibody, served as a control. Following laser irradiation, the cells 
were stained with calcein AM, which indicated a circular area of cell death corresponding 
to the spot size of the laser for those cells incubated with targeted nanoshells. No cell 
death was observed for cells incubated with non-targeted nanoshells or for cells receiving 
only laser irradiation (Figure 14). 
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Figure 14 Therapy of SKBr3 cells using HER2-targeted nanoshells. Calcein staining reveals cell death in 
cells receiving NIR-laser treatment following exposure to HER2-targeted nanoshells[63]. 
Targeting the tumor vasculature itself has also been investigated[64]. Vascular 
endothelial growth factor receptor-2 (VEGFR-2), a tyrosine kinase receptor expressed on 
the surface of endothelial cells that is upregulated in tumor vasculature[65-67], was the 
target of choice. Targeting to VEGFR-2 using VEGF165 and anti-VEGFR-2 antibodies 
was explored. Parallel experiments were run investigating VEGFR-2 targeting in vitro. 
In one experiment, VEGF165 was conjugated to the nanoshells surface and in the other, 
anti-VEGFR-2. Murine endothelial Miles Sven 1 (MSI) cells and human dermal 
fibroblasts (HDFs) were incubated with VEGF or VEGFR-2 conjugated nanoshells. The 
cells were then irradiated with a NIR laser at 60 W/cm2 for 7 minutes over a 1.5 mm 
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diameter spot. Live/dead staining revealed a circular area of cell death the same spot size 
as that of the laser for VEGF and anti-VEGFR-2 conjugated nanoshells on MSI cells 
(Figure 15). No cell death of MSI cells was observed as a result of non-targeted 
nanoshells and no cell death of the HDFs occurred. 
Figure 15 Cell viability and silver staining after laser + anti-VEGFR conjugated nanoshell therapy. A) 
Circular area of cell death as a result of laser exposure to MS 1 cells incubated with anti-VEGFR 
nanoshells. B) No cell death resulting from non-targeted nanoshells. C) Silver staining verifies binding of 
anti-VEGFR nanoshells to MSI cells. D) Very minimal binding of non-targeted nanoshells to cells[64]. 
In order to study VEGF nanoshell targeting in vivo, female BALB/c mice were 
inoculated subcutaneously with CT-26 cells, forming a tumor on the right hind flank[64]. 
Tumors were allowed to grow 6-10 days after which they were injected with nanoshells 
through the tail vein. Three mice received VEGF nanoshells plus laser, three received 
non-targeted nanoshells plus laser, and three received no treatment. The nanoshells were 
allowed to accumulate in the tumor for 2 hr prior to laser exposure (820 nm, 4 W/cm2, 3 
minutes). Measurements of the tumor size in the days following laser treatment revealed 
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a minimization of tumor burden in the mice receiving VEGF-nanoshells but not in those 
receiving non-targeted nanoshells or no therapy (Figure 16). 
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Figure 16 Average tumor area of tumors on the day of treatment and 14 days after treatment. The average 
tumor area for mice receiving VEGF-nanoshells was comparable to the tumor size on the day of the 
treatment. The tumors of mice receiving either non-targeted nanoshells or no treatment continued to 
grow[64]. 
1.6.5 Nanoshell-Assisted imaging techniques 
As mentioned previously, nanoshells can be designed to strongly scatter light, 
which is of great use in optical imaging modalities. Their use in in vitro dark-field 
imaging of HER2 expression using has been described[63, 68, 69]. Nanoshells with a 
120 nm core radius and a 35 nm shell thickness were conjugated to anti-HER2 and 
incubated with HER2+ SKBr3 cells and then imaged under dark-field magnification[69]. 
Figure 17 demonstrates the contrast provided by targeted nanoshells as opposed to non-
targeted or the absence of nanoshells. 
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Figure 17 Scattering properties of nanoshells. (a-c) High magnification (40X) dark field images of HER2+ 
SkBr3 cells incubated with no nanoshells, angi-IgG-labeled nanoshells, and HER-2 targeted nanoshells. 
(d-f) Dark-field images (10X) of HER2+ cells[69]. 
Nanoshells have also been investigated in the use of signal enhancement in optical 
coherence tomography (OCT). Loo et al. compared OCT images of saline, a suspension 
of 2 um polystyrene microspheres, and a nanoshell (100-nm core radius, 20-nm shell 
thickness) suspension at a concentration of lxl09 NS/ml. Basing OCT intensity on a log 
scale where black=255 and white=0, the average intensity of saline was 247 while 
nanoshell intensity was 160, showing that nanoshells provided higher contrast[68]. 
Due to their ability to be designed to both scatter and absorb light, nanoshells can 
be used in combined imaging and therapy applications. This was first demonstrated with 
an in vitro study in which SKBr3 cells were incubated with HER2-targeted nanoshells 
followed by laser irradiation (820 nm, 0.008 W/m2, 7 min)[63]. Cell viability was then 
assessed via calcein staining and nanoshell binding was assessed through silver staining. 
The nanoshells bound to cells were viewed using darkfield microscopy. Figure 18 shows 
increased contrast and cytotoxicity in cells resulting from targeted nanoshell/laser therapy 
compared to both cells treated with non-targeted nanoshells and laser irradiation and cells 
treated with laser only. 
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Figure 18 Combined imaging and therapy of SKBr3 cells using HER2-targeted nanoshells. (Top row) 
Dark-field imaging. (Middle row) Calcein staining revealing cell death in nanoshell-treated cells. (Bottom 
row) Silver stain imaging of targeted nanoshells[63]. 
Gobin et al. investigated the application of nanoshells in combined imaging and 
therapy in vz'vo [70]. Nanoshells were made with a core diameter of 119 nm and a shell 
thickness of 12 nm. Mice were subcutaneously inoculated with CT-26 cells on the right 
hind flank, forming a tumor. Tumors were allowed to grow to a diameter of 5 mm after 
which PEG-conjugated nanoshells were injected into the mice through the tail vein. PBS 
was injected into one group of the mice as a control. After allowing an accumulation 
time of 20 hr, the tumors were imaged using OCT. Representative OCT images (Figure 
19) reveal significant increase in contrast intensity in tumors of mice treated with 
nanoshells and no contrast intensity increase in tumors of mice not receiving nanoshells. 
Quantification of this intensity increase is shown in Figure 20. 
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Figure 19 Representative OCT images of skin/muscle areas (A and B) or tumor areas (C and D) of mice 
injected with PBS (A and C) or nanoshells (B and D). Increase in contrast between normal tissue and 
tumor tissue is apparent in mice with nanoshells but not those injected with PBS[70]. 
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Figure 20 Quantification of OCT image intensity reveals a significant difference in intensity between 
normal (gray bar) and tumor tissue (black bar) of mice injected with nanoshells and no significant 
difference between the intensity of tissues in those mice injected with PBS[70]. 
Following OCT imaging, mice were randomly divided into three groups. These 
comprised of the treatment group (nanoshells + laser), sham group (PBS + laser), and 
control group (untreated). The tumors of the treatment and sham groups were irradiated 
with a NIR laser (808 nm, 4 W/cm2, 3 min), after which tumor size and animal survival 
were monitored for the next 7 weeks. Twelve days after treatment, all but 2 tumors in the 
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treatment group had regressed while tumors of those mice in the sham and control groups 
continued to grow (Figure 21 A). By day 21 after treatment, survival of the treatment 
group was significantly greater than either the sham or control groups (Figure 2IB). 
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Figure 21 Tumor size and survival following NAPT. (A) Tumor size before treatment and 12 days after 
treatment for treatment group (white bar), sham group (grey bar), and control group (black bar). Tumor 
size decreased for those mice receiving nanoshells + laser treatment but increased in those receiving PBS + 
laser and those receiving no treatment. (B) Kaplan-Meier survival curve indicates survival of 80% of those 
mice receiving nanoshells + laser treatment 7 weeks after treatment (black line)[70]. 
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1.6.6 Advantages of Nanoshell Therapy 
There are many advantages to using nanoshells in treatment of tumors as opposed 
to current treatment methods. The peak optical absorption of nanoshells can be tuned to 
the NIR region and can therefore absorb light and generate heat when irradiated with a 
NIR laser. Due to the low absorption and high transmittance of light in the NIR range in 
tissues, irradiation does not cause damage to the skin or surrounding tissue. This 
therefore provides a safe non-invasive method of photothermal ablation of tumors. 
Current chemotherapeutic therapy involves systemically administering anti-
proliferative drugs, often destroying healthy cells. The facile conjugation of biomolecules 
to the nanoshell surface enables tumor-specific targeting of the nanoshells. The 
nanoshells can be targeted to molecules on the surface of the tumor cells[63] or to 
receptors on the endothelium, specifically targeting the tumor vasculature [64]. This 
tumor-specific targeting enables more rapid accumulation of the nanoshells within the 
tumor [60, 64]. Laser irradiation of the tumor containing targeted nanoshells results in 
localized tumor cell death. 
The combined scattering and absorbing properties of nanoshells enables them to 
be used in combined imaging and therapy applications[63, 68, 69] Subsequently, 
nanoshells can be used simultaneously as an imaging contrast agent and therapeutic 
agent. Following injection of the nanoshells, tumors can be localized through scatter-
based imaging methods and then immediately irradiated for tumor photothermal ablation. 
This is potentially advantageous to the patient due to more rapid therapy upon tumor 
localization. 
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1.7 Project Summary 
In order to increase specificity of the nanoshell therapy to the tumor area and to 
limit unwanted heating in surrounding tissues, the nanoshells were cross-linked with a 
peptide degradable by the MMPs in the tumor interstitium. These nanoshells experience 
a broadening and red-shifting of the peak, resulting in the inability to generate as much 
heat when irradiated at their initial peak wavelength. Once the linker is degraded by the 
MMPs in the tumor, the peak properties return, leading to the ability to generate heat and 
cause tumor cell death. Those nanoshell aggregates that remain outside the tumor area 
and are therefore not exposed to higher levels of MMPs will remain aggregated and 
unable to generate high amounts of heat. 
Due to the dampened peak optical properties, the nanoshell aggregates will not 
absorb as much energy and therefore not experience as extensive heating as dispersed 
nanoshells. The peak optical properties should be regained by degradation of the linker 
by the matrix metalloproteases (MMPs) activated in the tumor. 
The degradable peptide selected was GGLGPAGGK, due to its collagenase-
specificity. A 2300 Da poly (ethylene) glycol (PEG) chains was added to each end of the 
peptide in order to provide the enzyme enough space to fit between the nanoshells in 
order to cleave the peptide. 
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Chapter 2: Materials and Methods 
2.1 Fabrication of Gold-Silica Nanoshells 
Nanoparticles consisting of a dielectric silica ' • 
core and a gold shell were made according to the four-
step process outlined below[53]. 
2. 
2.1.1 Silica Particle Formation 
Solid silica nanoparticles were formed according -, 
to the Stober method[71]. For particle sizes in the 
range of 80-140 nm, the following procedure was . 
followed. Concentrated ammonium hydroxide at a 
volume of 2.5-3.1 mL, (NH4OH, Aldrich, 28%) was 
added to 45 mL of ethanol (EtOH). The core size 
Figure 22. Four-step synthesis of 
correlates with the amount of NH4OH added. While stirr silica-gold nanoshell fabrication 
tetraethylorthosilicate (TEOS, Aldrich 99.999%) was added after which the mixture 
rapidly stirred for 1 min. The mixture was allowed to stir slowly for a period of at least 8 
hr while the condensation reaction of the silica progressed. The silica nanoparticles were 
centrifuged twice (1900 x g, 30 min.) each time being re-suspended in fresh 100% ethanol. 
The sizes of the silica nanoparticles were measured using scanning electron microscopy 
(SEM; Quanta FIE 400). Batches of particles with a polydispersity less than 10% were 
used in the subsequent steps. 
2.1.2 Functionalization of Silica Particles 
To promote binding of small gold colloid to the silica particle, the surface was 
terminated with amine groups[53, 72]. 3-aminopropyltriethoxysilane (APTES, Aldnch, 
99%) at a volume of 100-200 uL was added to each batch of cores and allowed to react 
for at least 8 hr. The cores were then boiled at constant EtOH volume for 2 hr to 
promote covalent bonding of the silane groups to the surface of the silica particles. The 
cores were then again centrifuged twice (1900 xg, 30 min.) and re-suspended in fresh 
EtOH. 
2.1.3 Gold Colloid Formation and Seed Growth 
Gold colloid was prepared as described by Duff[73]. A stock solution of 
tetrakis(hydroxymethyl)phosphonium chloride (THPC, Aldrich) was made by the 
addition of 400 |il of THPC to 33 ml of deionized (DI) water. While stirring rapidly, 4 
ml of the THPC stock and 1.2 ml of 1 M NaOH (Aldrich) were added to 180 ml of DI 
water chilled to 4°C. After allowing the solution to stir for 5 min, 6.75 ml of 1% 
chloroauric acid (HAuCLt, Aldrich, 99.999%) was added, resulting in a light reddish-
brown suspension of colloid. The colloid was aged 2-3 days at room temperature. 
The "seed particle," a silica nanoparticle with gold colloid bound to the surface 
served as the precursor to the gold-silica nanoshell[53, 72]. To make seed particles, a 180 
ml volume of colloid was mixed with 1 ml of functionalized cores at 4 wt%. 9 mL of 1 M 
NaCl was also added to the mixture. This was allowed to react up to 3 days at 4°C. The 
resulting seed particles were washed with DI water through centrifugation (1300 x g, 15 
min, performed twice) with ultrasonic probe resuspension. Finally, seed particles were 
diluted with DI water to have an extinction of 0.1 A.U. at a wavelength of 530 nm. 
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2.1.4 Shell Formation 
The final step in formation of the nanoshell is the formation of the gold shell on the 
surface of the silica core. 3 ml of 1% HAuCU was added to 200 ml of 1.8 mM potassium 
carbonate (K2CO3, Aldrich) and allowed to age a minimum of 12 hr. The necessary 
volume ratio of seed suspension to potassium carbonate solution to produce nanoshells 
with the desired extinction characteristics was determined by examining the UV-Vis 
spectra of varying ratios at a total volume of 1 mL. Once the appropriate ratio was 
determined, the appropriate volume ratio is scaled up to produce larger amounts of 
nanoshells. Seed was mixed with the HAUCI4/K2CO3 solution and while rapidly mixing, 
formaldehyde at a volume of 10 ul per 1 ml HAUCI4/K2CO3 was added, reducing the gold 
and resulting in a contiguous gold shell over the surface of the silica particle. The 
characteristics of the nanoshell were determined by spectral extinction profile using a UV-
Vis spectrophotometer (Cary Bio 50) in the range of 400 - 1100 nm. After analysis the 
nanoshells were washed with a 1.8 mM potassium carbonate solution then centrifuged 
(700 x g, 20 min, performed twice). The final nanoshells were re-suspended in DI water. 
2.2 Peptide Synthesis 
The collagenase-sensitive peptide, GGLGPAGGK, was made using Fmoc solid 
phase peptide synthesis. This method involves the use of a polystyrene bead resin on 
which the amino acids are added one by one. The schematic of solid phase peptide 
synthesis is shown in Figure 23. After addition of the first amino acid to the polystyrene 
bead, the Fmoc protecting group is removed. The C terminus of the next amino acid is 
activated after which it is coupled to the amino acid on the resin. This process is 
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completed until the desired amino acid sequence is achieved. The last Fmoc group and 
any other side chain protecting groups are then removed followed by cleavage of the 
peptide from the resin. 
i) Depmfceetiean 
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Figure 23. In solid phase peptide synthesis, amino acids are added in chain-like fashion onto a solid bead 
resin. Amino acid coupling involves the following steps: (1) removal of the protecting group from amino 
acid A, (2) activation of the C-terminus of amino acid B, and (3) coupling of the amino acids A and B. 
These steps are repeated until the peptide chain reaches the desired length after which the final protecting 
group is removed (4) and then the peptide chain is cleaved from the resin (Adapted from [74]). 
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The peptide was synthesized using Fmoc solid-phase synthesis on an automated peptide 
synthesizer (Aapptec). The following solutions of organic solvents were made up for the 
synthesis process: 25% piperidine (Sigma) in dimethylformamide (DMF, Sigma), 2M 
diisopropylethylamine (DIPEA, Sigma) in 1:1 DMF:dichloromethane (DCM, Applied 
Biosystems), and 0.5M HBTU (o-Benzotriazol-l-yl-N,N,N',N'-tetramethyluronivim 
hexafluorophosphate, Novabiochem) in DMF. 0.2273 g Fmoc-Lys(Boc)-Wang resin 
(Novabiochem) was placed in each of the 8 wells on the reaction block. Amino acids 
were dissolved to 0.5 M in appropriate volumes of 1:1:1 volumetric ratios of N-methyl-
pyrrolidinone (NMP, Applied Biosystems):DCM:DMF. The synthesizer performed the 
steps of solid-phase peptide synthesis including removal of the Fmoc protecting group, 
amino acid activation and coupling, and washing. Upon completion of the peptide 
synthesis, the peptide was cleaved from the polystyrene resin using a cleavage cocktail of 
95% trifluoroacetic acid (TFA, Sigma), 2.5% triisopropylsilane (TIPS, Sigma), and 2.5% 
water. This cocktail reacted with peptide-resin on the reaction block in the synthesizer 
for 3 hr after which the solution, now containing the solubilized peptide was collected. 
Upon completion of the cleavage step, the TFA was removed from the peptide via rotary 
evaporation (Buchi Rotavapor R-200). The remaining solution was added to chilled ethyl 
ether anhydrous (Fisher Scientific), resulting in precipitation of the peptide. Residual 
cleavage cocktail was removed from the precipitate via centrifugation (1900 x g, 30 
minutes, repeated 5 times). After the final centrifugation step, the supernatant was 
decanted and the peptide was left to dry overnight. After drying, the peptide was 
dissolved in water and dialyzed against DIH2O using a 500 Da molecular weight cut-off 
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membrane for 8 hr, changing the water every hour. Upon completion of dialysis, the 
peptide solution was frozen and then lyophilized. The final lyophilized peptide was 
characterized via MALDI-TOF mass spectrometry (MS Autoflex) and stored under argon 
at-80°C. 
2.3 PEG Conjugation to Peptide 
The peptide sequence GGLGPAGGK was conjugated to a bi-functional PEG 
molecule, orthopyridyl sulfide-PEG-n-hydroxysuccinimide (OPSS-PEG-SPA, Nektar, 
M W 2000) by reacting a 2.4 molar excess of PEG to peptide in sodium bicarbonate 
buffer. This allowed primary amines on both ends of the peptide, both on the arnino-
terminus and the lysine side-chain, to react with the PEG forming peptide bonds via 
cleavage of the SPA group (Figure 24). 
GGLGPAGGK + 
o 
I y ^ NaHC03 (pH 8.5) 
OPSS-PEG-SPA J 
OPSS-PEG-GGLGPAGGK-PEG-OPSS 
Figure 24. Reaction scheme of PEG-peptide conjugation. The PEG molecule binds to the free amine on 
each end of the peptide chain via cleavage of the SPA group. 
After reacting overnight on a rocker at 4°C, the PEG-peptide-PEG was dialyzed 
overnight against a membrane of MWCO 3500 Da, lyophilized, and stored frozen in 
powder form. The PEG-peptide-PEG conjugation was characterized through gel 
permeation chromatography in order to determine the presence of pure PEG-LGP A-PEG 
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with no PEG-LGPA or un-reacted OPSS-PEG-SPA (PL-ELS 1000, Polymer 
Laboratories). 
2.4 PEGvlation of Nanoshells 
In order to prevent nonspecific protein adsorption to the gold surface, the 
nanoshells were functionalized with PEG-thiol (PEG-SH, Laysan, 5000 Da), the amount 
of which to be added was determined using the stability test, described below. The thiol 
group on the end of the PEG chain strongly binds to the gold layer forming a monolayer 
on the nanoshell surface. Following addition of PEG-SH, the nanoshell suspension was 
vortexed to ensure proper mixing and then was allowed to react on a rocker at 4°C for 12 
hours. 
2.5 Nanoshell Stability Test 
A stability test was performed in order to determine the minimum amount of PEG-
SH necessary for complete coverage of the nanoshells surface. After washing, nanoshells 
were diluted to a concentration of 4.5 x 109 NS/ml and aliquoted into UV-Vis cuvettes at a 
1 ml volume. 4 ul of PEG-SH at concentrations of 0, 0.5, 1.0,1.5 mM was added to 
nanoshell cuvettes after which the cuvettes were vortexed and incubated at 4°C overnight. 
100 ul of a 1 mM sodium chloride (NaCl) solution was added to each cuvette of 
nanoshells and the change in the UV-Vis spectrum was recorded every 10 minutes over a 
period of 2 hours. Those nanoshells that did not have sufficient surface coverage of the 
PEG-SH aggregated and fell out of solution upon addition of salt to the suspension while 
those that had full coverage remained suspended. The lowest volume of PEG-SH added 
to the nanoshells among those that remained suspended upon addition of salt was 
considered the lowest amount necessary to provide sufficient surface coverage and 
stabilize the nanoshells. 
2.6 Enzyme-Induced Nanoshell Aggregation Test 
The addition of an enzyme to an aqueous suspension of gold nanoparticles, as is 
necessary to degrade the peptide linker, can result in aggregation of the nanoparticles. 
Therefore, highest enzyme concentration at which the nanoparticles remain disperse in 
the suspension must be determined. Silica-gold nanoshells were diluted to a 
concentration of 4x109 particles/ml. Proteinase K (Invitrogen) was added to the 
nanoshells resulting in final enzyme concentrations of 0.0025, 0.005, and 0.01 mg/ml. 
The UV-vis spectrum of each nanoshells suspension was recorded every 10 minutes for 2 
hours after addition of the enzyme. Nanoshell aggregation was characterized by a 
decrease in the peak extinction. 
2.7 Heat Measurements of PEG-dithiol-Crosslinked Nanoshells 
Nanoshells were made as described above and diluted to a concentration of 4x109 
NS/ml. 0.5 \x\ of 0.1 mM PEG dithiol (SH-PEG-SH, Nektar) was added to 1 mL of the 
nanoshell suspension and allowed to react overnight. UV-Vis scans were taken every 24 
hr and the peak absorbance value was recorded. Each cuvette of nanoshells and PEG 
dithiol was irradiated with a 808 nm laser at 3 watts for 5 minutes. The temperature of 
the nanoshell suspension was measured with a thermocouple placed outside the laser 
beam (Omegaette HH500). The final change in temperature over 5 min was determined 
and averaged. 
2.8 Crosslinking Nanoshells with a Degradable Linker 
PEG-LGPA-PEG was mixed with PEG-SH at a final concentration of that which 
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was determined to be the lowest concentration necessary to stabilize the nanoshells. 
Nanoshells were concentrated to 4x109 NS/ml and then aliquoted into UV-Vis cuvettes at 
a volume of 1 ml. 4 ul of the PEG-LGPA-PEG mixtures were added to the appropriate 
cuvette, immediately after which the nanoshell suspensions were vortexed for 1 second. 
As a control, the same experiment was run in parallel with PEG-dithiol (SH-PEG-SH, 
3400 Da, Laysan Bio Inc.) in place of the PEG-LGPA-PEG. The nanoshells/linker 
mixtures were allowed to react on the benchtop. The UV-Vis spectrum was recorded 1 hr 
and 2 hrs following addition of the PEG-LGPA-PEG/PEG-SH or SH-PEG-SH/PEG-SH 
mixture. A decrease in the peak extinction indicated cross-linking of the nanoshells. 
2.9 Degradation of Peptide Linker 
Two hours after addition of the PEG-LGPA-PEG/PEG-SH or SH-PEG-SH/PEG-
SH mixture, 1.26 \xl of 2 mg/ml collagenase (Type XI, Sigma-Aldrich) was added to each 
cuvette for a final concentration of 0.0025 mg/ml collagenase. The UV-Vis spectrum of 
each sample was recorded 3 hours following addition of the collagenase. 
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Chapter 3: Results 
3.1 Heating Test 
Following addition of 0.5 i^l 0.1 mM PEG dithiol to the nanoshell suspension, the 
peak extinction of the nanoshells decreased overtime as shown in Figure 25. Those 
nanoshells to which no PEG dithiol was added remained disperse and there was no 
change in peak extinction over time. 
Change in Nanoshell Peak Extinction as a Result of 
PEG Dithiol-Induced Aggregation 
•0.1 mM 
• bare NS 
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Figure 25 The aggregation of nanoshells resulting from introduction of SH-PEG-SH into the 
suspension is dependent on the amount of PEG dithiol. Nanoshell aggregation occurred when PEG 
dithiol at a concentration of 0.1 mM is added but not 1 or 10 mM. 
Temperatures of the nanoshell suspensions were recorded with a thermocouple. Those 
nanoshells cross-linked with PEG-dithiol as indicated by a lower peak extinction had a 
lower change in temperature (AT=22°C) after 5 minutes of heating, than bare nanoshells 
(AT=67°C), as shown in Figure 26. 
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Figure 26 Temperature readings of nanoshell suspensions revealed a lower change in heating in those with 
aggregated nanoshells than those with disperse nanoshells. 
3.2 Enzyme-Induced Nanoshell Aggregation Test 
Varying amounts of proteinase K were added to nanoshells in order to determine 
the highest concentration at which nanoshell protein-induced aggregation would not 
occur. After 2 hours, the nanoshells remained disperse with a final enzyme concentration 
of 0.0025 mg/ml and 0 mg/ml (control) but aggregated as a result of the other enzyme 
concentrations (0.01 mg/ml, 0.005 mg/ml). 
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Figure 27 Proteinase K added to a nanoshell suspension at final concentrations of both 0.01 and 0.005 
mg/ml induced nanoshell aggregation. A final enzyme concentration of 0.0025 mg/ml allowed the 
nanoshells to remain suspended. 
This data suggests that after the nanoshells are cross-linked with a proteolytically 
degradable peptide, a maximum of 0.0025 mg/ml enzyme can be added to the nanoshell 
suspension in order to degrade the peptide and allow the nanoshells to remain suspended. 
3.3 Nanoshell Stability Test 
This test was performed in order to determine the amount of PEG-SH needed to 
sufficiently cover the nanoshell surface. Two hours after adding NaCl, the peak 
absorbance of the nanoshells with 4 u,l 1.5 mM PEG-SH had decreased by 6.8%, 1.0 mM 
by 7/9%, 0.5 mM by 10% and 0 mM by 99% (Figure 28). 
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Figure 28. Stability test of PEGylated nanoshells. Nanoshells to which 4 1^ of 1.5,1, and 0.5 mM PEG-
SH were added remained stable in the presence of NaCl. 
This test suggests that 4 JAI 0.5 mM PEG-SH added to nanoshells at a 
concentration of 4.5 x 109 NS/ml is sufficient to cover the surface of the gold nanoshell. 
This value was used in the subsequent study. 
3.4 Crosslinking Nanoshells 
0.5 mM SH-PEG-SH/PEG-SH and PEG-LGPA-PEG/PEG-SH mixtures of 
varying mole fractions were added to 1 mL volumes of nanoshells at a concentration of 
4.5 x 109 NS/ml. The UV-Vis spectra taken 3 hours after addition of SH-PEG-SH/PEG-
SH mixtures revealed a trend toward a greater decrease in peak absorbance with an 
increase of SH-PEG-SH mole fraction (Figure 29) The change in peak absorbance (initial 
absorbance - final absorbance) between mole fractions appears to increase exponentially. 
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Change in P e a k A b s o r b a n c e f o r Nanoshe l l s C ross l i nked w i t h SH-PEG-SH 
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Figure 29. Change in peak absorbance (initial peak absorbance - final peak absorbance) as a result of 
varying SH-PEG-SH mole fractions mixed with PEG-SH. The decrease in peak is greater with an increase 
in dithiol mole fraction. 
The UV-Vis spectra taken 3 hours after addition of PEG-LGPA-PEG/PEG-SH mixtures 
revealed a trend toward a greater decrease in peak absorbance among the middle PEG-
LGPA-PEG mole fractions, 0.4 being the highest 
Figure 30). 
Change in Peak Absorbance f o r Nanoshells Crosslinked w i t h PEG-LGPA-PEG 
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Figure 30. Change in peak absorbance as a result of varying PEG-LGPA-PEG mole fractions mixed with 
PEG-SH. The decrease in peak absorbance is greater for the middle PEG-LGPA-PEG mole fractions. 
3.5 Enzymatic Degradation of Peptide Linker 
After cross-linking the nanoshells, 1.26 i^l 2 mg/ml collagenase (0.0025 mg/ml 
final concentration) was added to those nanoshells that experienced the greatest 
decrease in peak absorbance (1 SH-PEG-SH mole fraction; 0.4 PEG-LGPA-PEG 
mole fractions) and the resulting peak absorbance was measured after 3 hours. 
Those nanoshells that had been cross-linked with SH-PEG-SH did not experience 
an increase in peak absorbance following collagenase addition, while those 
crosslinked with PEG-LGPA-PEG did experience an increase in peak absorbance 
(Figure 31). 
Peak Absorbance Following Enzymatic Degradation of the Linker 
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Figure 31. Peak absorbance before and after the addition of linker and after addition of collagenase. The 
peak increased for the nanoshells crosslinked with PEG-LGPA-PEG, but remained unchanged for the 
nanoshells crosslinked with SH-PEG-SH. 
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Chapter 4: Discussion 
These studies have shown nanoshells are able to be crosslinked with a dithiol 
molecule, resulting in a red-shifting and broadening of the UV-Vis spectrum. 
Crosslinked nanoshells were shown to experience a lower temperature change when 
irradiated with a near-infrared laser than dispersed nanoshells, as predicted by the 
presence of a lower peak absorbance value. This study provides a proof-of-principle 
demonstrating the difference in temperature change is large enough to cause tissue 
damage through the disperse nanoshells while not causing tissue damage through the 
crosslinked nanoshells. While the final temperature change of the crosslinked nanoshells 
in this study (22°C) is above the 15°C threshold for irreversible tissue damage[75], the 
difference between the final temperatures is enough so that if the laser power were 
reduced in order to lower the temperature change of the crosslinked nanoshells, the 
disperse nanoshells would still experience a temperature change high enough to cause 
irreversible tissue damage. 
The results from the crosslinking study suggest that the molar ratios of dithiol 
molecule to PEG-SH have an effect on nanoshell cross-linking. These studies were done 
by adding 4 [xl of a 0.5 mM thiolated molecule mixture to 1 ml nanoshells. For this 
thiolated molecule concentration, when the nanoshells were crosslinked with SH-PEG-
SH, the change in the peak absorbance seems to increase exponentially as the mole 
fraction increases up to 1. The data shows that when 4 ul of a 0.5 mM PEG-LGPA-
PEG/PEG-SH mixture is added to 1 ml nanoshells, the molar concentration of PEG-
LGPA-PEG and PEG-SH should be equal (0.4 - 0.6 PEG-LGPA-PEG mole fraction) in 
order to obtain the greatest decrease in peak absorbance. These results suggests that the 
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PEG-SH sterically aids the dithiol molecule (PEG-LGPA-PEG or SH-PEG-SH) in 
remaining upright on the nanoshell surface and exposing its other end to other nanoshells. 
Because of the length of the PEG-LGPA-PEG and SH-PEG-SH linker, a low presence of 
PEG-SH may allow the linker molecules to bend back on themselves, binding both ends 
to one nanoshell. The difference in dithiol molecule/PEG-SH ratios necessary to achieve 
the greatest decrease in peak may be due to the difference in length between PEG-LGPA-
PEG (5000 Da) and SH-PEG-SH (3400 Da). 
After crosslinking the nanoshells with SH-PEG-SH and PEG-LGPA-PEG, 
collagenase was added and the effects were observed. Three hours following addition of 
the enzyme to nanoshells crosslinked with PEG-LGPA-PEG, the peak made a significant 
increase, although not to the original peak absorbance value. Addition of enzyme to the 
nanoshells crosslinked with SH-PEG-SH made no difference in the peak absorbance. 
This increase in peak for PEG-LGPA-PEG crosslinked nanoshells but not for the SH-
PEG-SH crosslinked nanoshells indicates a degradation of the peptide linker leading to a 
dispersion of nanoshells crosslinked with PEG-LGPA-PEG. 
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Chapter 5: Conclusion 
This work has shown the ability of silica-gold nanoshells to be crosslinked with a 
dithiol molecule resulting in a decrease in peak absorbance. This decrease in peak 
absorbance was shown to correlate with a decrease in ability to generate heat upon laser 
irradiation, leading to a lower temperature change compared to disperse nanoshells. 
Crosslinking nanoshells with the degradable peptide-containing linker OPSS-
PEG-GGLGPAGGK-PEG-OPSS was shown to occur to the greatest extent when equal 
molar amounts of PEG-SH and the linker were present. The degradation of this linker 
was demonstrated by an increase in peak absorbance of the nanoshells following the 
addition of collagenase while those nanoshells crosslinked with a non-degradable linker 
did not experience an increase in peak absorbance. 
These studies have laid the groundwork for further development of protease-
activated nanoshell therapy. Further studies should be done to control aggregate size to 
one small enough to be able to extravasate out of the tumor vasculature. In vitro studies 
should be done with a highly metastatic cell line, such as HT-1080 in order to 
demonstrate successful nanoshell therapy when nanoshells crosslinked with a degradable 
linker are placed in the presence of secreted MMPs. 
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